103 related articles for article (PubMed ID: 1944437)
1. A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome.
Falloon J; Kovacs J; Hughes W; O'Neill D; Polis M; Davey RT; Rogers M; LaFon S; Feuerstein I; Lancaster D
N Engl J Med; 1991 Nov; 325(22):1534-8. PubMed ID: 1944437
[TBL] [Abstract][Full Text] [Related]
2. Open-label efficacy and safety trial of 42 days of 566C80 for Pneumocystis carinii pneumonia in AIDS patients.
Dohn MN; Frame PT; Baughman RP; Lafon SW; Smulian AG; Caldwell P; Rogers MD
J Protozool; 1991; 38(6):220S-221S. PubMed ID: 1818178
[TBL] [Abstract][Full Text] [Related]
3. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
Hughes W; Leoung G; Kramer F; Bozzette SA; Safrin S; Frame P; Clumeck N; Masur H; Lancaster D; Chan C
N Engl J Med; 1993 May; 328(21):1521-7. PubMed ID: 8479489
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.
Bozzette SA; Sattler FR; Chiu J; Wu AW; Gluckstein D; Kemper C; Bartok A; Niosi J; Abramson I; Coffman J
N Engl J Med; 1990 Nov; 323(21):1451-7. PubMed ID: 2233917
[TBL] [Abstract][Full Text] [Related]
6. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group.
El-Sadr WM; Murphy RL; Yurik TM; Luskin-Hawk R; Cheung TW; Balfour HH; Eng R; Hooton TM; Kerkering TM; Schutz M; van der Horst C; Hafner R
N Engl J Med; 1998 Dec; 339(26):1889-95. PubMed ID: 9862944
[TBL] [Abstract][Full Text] [Related]
7. 566C80, an antimalarial hydroxynaphthoquinone with broad spectrum: experimental activity against opportunistic parasitic infections of AIDS patients.
Gutteridge WE
J Protozool; 1991; 38(6):141S-143S. PubMed ID: 1818143
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with atovaquone on a treatment investigational new drug protocol for Pneumocystis carinii pneumonia.
White A; LaFon S; Rogers M; Andrews E; Brown N
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):280-5. PubMed ID: 7788426
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men.
Hughes WT; Kennedy W; Shenep JL; Flynn PM; Hetherington SV; Fullen G; Lancaster DJ; Stein DS; Palte S; Rosenbaum D
J Infect Dis; 1991 Apr; 163(4):843-8. PubMed ID: 2010637
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
Wordell CJ; Hauptman SP
Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial.
Gagnon S; Boota AM; Fischl MA; Baier H; Kirksey OW; La Voie L
N Engl J Med; 1990 Nov; 323(21):1444-50. PubMed ID: 2233916
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with atovaquone: a new drug for treating Pneumocystis carinii pneumonia.
Epstein LJ; Mohsenifar Z; Daar ES; Yeh V; Meyer RD
Am J Med Sci; 1994 Jul; 308(1):5-8. PubMed ID: 8010339
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis.
Hughes WT; Gray VL; Gutteridge WE; Latter VS; Pudney M
Antimicrob Agents Chemother; 1990 Feb; 34(2):225-8. PubMed ID: 2327770
[TBL] [Abstract][Full Text] [Related]
14. Atovaquone: a new antipneumocystis agent.
Artymowicz RJ; James VE
Clin Pharm; 1993 Aug; 12(8):563-70. PubMed ID: 8222520
[TBL] [Abstract][Full Text] [Related]
15. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome.
Allegra CJ; Chabner BA; Tuazon CU; Ogata-Arakaki D; Baird B; Drake JC; Simmons JT; Lack EE; Shelhamer JH; Balis F
N Engl J Med; 1987 Oct; 317(16):978-85. PubMed ID: 2958710
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
17. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group.
Dohn MN; Weinberg WG; Torres RA; Follansbee SE; Caldwell PT; Scott JD; Gathe JC; Haghighat DP; Sampson JH; Spotkov J; Deresinski SC; Meyer RD; Lancaster DJ
Ann Intern Med; 1994 Aug; 121(3):174-80. PubMed ID: 7880228
[TBL] [Abstract][Full Text] [Related]
18. [Randomized comparative study of secondary prevention of Pneumocystis carinii pneumonia in patients with acquired immunologic deficiency syndrome].
Höffken G; Elsing C; Ruhnke M; Franke M; Schrappe-Bächer M; Stellbrink HJ; Weiss R; Noack H; Petri M; Lode H
Med Klin (Munich); 1990 Apr; 85 Suppl 2():281-5. PubMed ID: 2197538
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS.
Kazanjian P; Armstrong W; Hossler PA; Lee CH; Huang L; Beard CB; Carter J; Crane L; Duchin J; Burman W; Richardson J; Meshnick SR
J Infect Dis; 2001 Mar; 183(5):819-22. PubMed ID: 11181161
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients.
Martin MA; Cox PH; Beck K; Styer CM; Beall GN
Arch Intern Med; 1992 Mar; 152(3):523-8. PubMed ID: 1546914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
